Articles

BRP (BRINP2-related peptide) is a computationally identified 12-amino-acid peptide that suppresses appetite and reduces fat mass in rodents and minipigs via a hypothalamic cAMP–PKA–CREB–FOS signaling axis entirely distinct from incretin pathways. Unlike GLP-1 receptor agonists, BRP produced no conditioned taste aversion or delayed gastric emptying in preclinical models, while generating a comparable or stronger hypothalamic Fos response than GLP-1 itself.

The 2026 Springer review establishes tirzepatide as a genuine multi-organ metabolic integrator: its dual GIP/GLP-1 receptor co-agonism simultaneously reshapes adipose lipolysis, hepatic lipid flux, skeletal muscle glucose uptake, and pancreatic beta-cell function. The net body composition result is 22 to 25 percent total weight loss with approximately 75 percent attributable to fat mass, outperforming semaglutide monotherapy in comparative analyses.

Incretin mimetics suppress appetite so aggressively that absolute protein intake collapses well below the minimum threshold needed to sustain muscle protein synthesis. Deliberate high-protein targeting restores leucine-triggered mTORC1 signalling. Incretin-stimulated insulin simultaneously amplifies postprandial amino acid uptake. Together these inputs form a mechanistically complementary pairing that 2024–2025 trial data increasingly supports.

A 2026 narrative review in Pharmaceuticals (MDPI, DOI: 10.3390/ph19020297) maps semaglutide's pleiotropic effects onto two domains relevant to performance practitioners: oncogenic signalling risk and mitigation of chemotherapy-driven cardiotoxicity. The net oncogenic signal is confounded by obesity itself; the cardiotoxicity mitigation data are preclinical but mechanistically precise. Both domains alter risk stratification for specific user profiles.

FDA scientists' pre-meeting briefing documents for the July 23–24, 2026 PCAC hearing recommended against adding TB-500, BPC-157, and MOTS-C to the 503A Bulk Drug Substances List. The core finding: zero human clinical studies support the proposed uses for TB-500 and MOTS-C, while BPC-157's preclinical data cannot substitute for absent human efficacy evidence under the 503A standard.

A 2026 review in International Journal of Molecular Sciences (Yuan et al., MDPI) confirms BPC-157 operates across two mechanistically distinct axes simultaneously: a regenerative axis driven by angiogenesis, collagen synthesis, and fibroblast activation, and an analgesic axis mediated through nitric oxide modulation and dopaminergic–opioid system interactions. Both axes are documented exclusively in preclinical models; no human RCT data exists.

BPC-157 dose- and time-dependently increases growth hormone receptor (GHR) expression in tendon fibroblasts at both mRNA and protein levels — documented by Chang et al. (2014, Molecules) and reaffirmed in the 2026 Matek review. The mechanism amplifies GH-axis signaling locally in tendon tissue, sensitising fibroblasts to circulating GH without raising systemic GH output.

A 2026 review in Saudi Medical Journal (PMC13227446) confirms semaglutide delivers clinically meaningful glycaemic control, 15 to 17 percent body-weight reduction, approximately 20 percent cardiovascular risk reduction, and emerging hepatic and renal benefits. The critical performance caveat is lean-mass attrition of 30 to 40 percent of total weight lost, demanding deliberate resistance-training and protein-intake countermeasures.

GLP-1 receptor agonists drive 25–40% of total weight loss from lean tissue — a ratio that directly suppresses resting energy expenditure. Growth hormone secretagogues counter this via the GH→IGF-1→mTOR axis, stimulating muscle protein synthesis and preferentially mobilising visceral adipose tissue. The mechanistic case is strong; RCT-level co-administration data remain limited as of 2026.

Seven peptides — BPC-157 (free base and acetate), KPV, TB-500, MOTS-C, Emideltide (DSIP), Semax, and Epitalon — are formally scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026. A favorable committee recommendation initiates the rulemaking pathway toward the FDA's 503A Bulk Drug Substances List, ending each substance's Category 2 restriction status.

In a caloric deficit, circulating IGF-1 drops ~40% and leucine's mTORC1 signal weakens due to reduced Sestrin2 displacement. IGF-1 LR3—engineered to evade IGF-binding proteins—maintains receptor-level PI3K/Akt input independently of energy status, while leucine supplies a parallel, lysosome-anchored RAGULATOR/Rag GTPase signal. The two inputs converge on mTORC1-S6K1/4E-BP1 through mechanistically distinct but additive routes.

During rapid GLP-1-driven weight loss, semaglutide creates a sustained caloric deficit that elevates muscle proteolysis — STEP 1 trial data show roughly 39–40% of total weight lost is lean mass. BPC-157 counters this via GH-receptor upregulation, VEGFR2-mediated angiogenesis, and satellite-cell activation, mechanistically targeting the same catabolic pathways GLP-1 agonists leave unaddressed.